Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000)

Cancer Investigation
Joan H Schiller

Abstract

Expression of epidermal growth factor and its transmembrane receptor (EGFR) stimulates tumor growth. Matuzumab is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth, and provides a clinical benefit for some patients. The plasma half-life (6-10 days) and pharmacodynamic activity allow flexible dosing on weekly, every-2-week, and every-3-week schedules. Matuzumab has shown single-agent antitumor activity in heavily pretreated patients with a variety of tumors, with a favorable safety profile. Skin rash is the most common toxicity, but is severe (Grade 3) in < 1 percent. This article describes preclinical and clinical development of matuzumab.

References

Jan 15, 1990·International Journal of Cancer. Journal International Du Cancer·K YoshidaE Tahara
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·H SunadaC L MacLeod
May 1, 1987·British Journal of Cancer·D VealeA L Harris
Dec 1, 1986·Bioscience Reports·S Cohen
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaJ Mendelsohn
Feb 25, 2000·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·I PorebskaT Bojarowski
Nov 21, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A McKayH L McLeod
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John Mendelsohn, Jose Baselga
Sep 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschWilbur A Franklin
Oct 8, 2003·Diseases of the Colon and Rectum·Reinhard KoppAndreas Pfeiffer
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Udo VanhoeferJosé Baselga
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
May 4, 2004·The Lancet Oncology·Marion Harris
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Murray B ResnickVictor E Pricolo
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José Baselga, Carlos L Arteaga
Jul 15, 2005·The New England Journal of Medicine·Ming-Sound TsaoFrances A Shepherd
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Román Peréz-Soler, Leonard Saltz
Sep 15, 2005·Gynecologic Oncology·Chad A LivasyRuth A Lininger
Sep 15, 2005·International Journal of Cancer. Journal International Du Cancer·Mitsuhiko HanawaAkishi Ooi
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lupe G Salazar, Mary L Disis
Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christiane D ThieneltKaren Kelly
Nov 23, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R Hirsch, Paul A Bunn
Nov 23, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francisco RobertMichael Needle
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara BurtnessUNKNOWN Eastern Cooperative Oncology Group
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado

❮ Previous
Next ❯

Citations

Aug 15, 2009·Cell Communication and Signaling : CCS·Thomas SeufferleinGötz von Wichert
Nov 11, 2008·Experimental Cell Research·Karl R Schmitz, Kathryn M Ferguson
Feb 12, 2009·International Journal of Cancer. Journal International Du Cancer·Thomas K HoffmannHenning Bier
Jun 24, 2011·MAbs·Stephen J DemarestJianying Dong
Jun 8, 2012·Cancer Immunology, Immunotherapy : CII·Edzard SpillnerIngke Braren
Mar 27, 2018·The Journal of Pharmacy and Pharmacology·Shima Moradi-KalbolandiLeila Farahmand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.